BIOMERIEUX (EPA:BIM) | Finanzwire

Basculer en Français

8299	Companies
114942	Keywords
55348	Articles
62469	Press releases

Home
Companies
BIOMERIEUX

REGULATED PRESS RELEASE

published on 03/27/2024 at 18:01, 7 months 24 days ago

bioMérieux receives Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
bioMérieux receives 510(k) clearance and CLIA-waiver for BIOFIRE SPOTFIRE R/ST Panel, enhancing diagnostic capabilities for respiratory and sore throat infections globally

BioMérieux 510(k) Clearance BIOFIRE SPOTFIRE R/ST Panel CLIA-waiver Approval Diagnostic Testing
BRIEF

published on 03/25/2024 at 17:35, 7 months 26 days ago

BIOMERIEUX Combined General Meeting Scheduled for May 23, 2024

Shareholders BioMérieux General Assembly Documentation Voting Conditions
REGULATED PRESS RELEASE

published on 03/14/2024 at 07:01, 8 months 7 days ago

bioMérieux – 2023 Financial Results
BRIEF

published on 03/04/2024 at 11:42, 8 months 17 days ago

BioMérieux announces its voting rights figures for February 2024

Share Capital Voting Rights BioMérieux Regulation February 2024
REGULATED PRESS RELEASE

published on 01/16/2024 at 07:01, 10 months 5 days ago

bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
bioMérieux, a world leader in in vitro diagnostics, announces the appointment of two new Executive Committee members, Dr. Charles K. Cooper and Céline Roger-Dalbert, to lead Medical Affairs and Research & Development, respectively. Dr. Cooper brings extensive medical and leadership background from Siemens Healthcare Diagnostics and U.S. Food & Drug Administration, while Céline Roger-Dalbert boasts over 25 years of in vitro diagnostic experience, with significant contributions to new product launches and over 20 patent applications. Their nominations signify bioMérieux's commitment to addressing global patients' needs and driving innovation, aligning with the company's strategy. For more information, visit www.biomerieux.com.

BioMérieux Medical Affairs Research And Development In Vitro Diagnostics Executive Committee Members
REGULATED PRESS RELEASE

published on 01/08/2024 at 08:22, 10 months 13 days ago

bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
bioMérieux has acquired LUMED, a software company specializing in clinical decision support systems to optimize antimicrobial prescriptions and monitor healthcare-associated infections. This acquisition reinforces bioMérieux's commitment to combat antimicrobial resistance and improve infection prevention and control through advanced software solutions.

BioMérieux LUMED Antimicrobial Resistance Clinical Decision Support System Infection Prevention And Control
REGULATED PRESS RELEASE

published on 10/26/2023 at 07:01, 1 year ago

bioMérieux – Third-Quarter 2023 Business Review
REGULATED PRESS RELEASE

published on 10/19/2023 at 08:00, 1 year 1 month ago

bioMérieux makes strategic investment in Oxford Nanopore
REGULATED PRESS RELEASE

published on 10/13/2023 at 07:02, 1 year 1 month ago

bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1), a test for improved assessment of patients with mild traumatic brain injury, including concussion

Accesswire

Published on 11/21/2024 at 14:15, 13 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 28 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 28 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 28 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 28 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 12 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 13 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 28 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 13 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 53 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 30 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 8 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 43 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 43 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE